Specifically, the Court concludes that Plaintiffs are likely to prevail * based on the right to personal autonomy set out in Section 1 of the Kansas Constitution Bill of Rights and a parent's fundamental right to make medical decisions for their children,
The U.S. Attorney's Office in the Northern District of Texas has issued a subpoena for the medical records of trans youth who received gender-affirming care from NYU Langone Health, a New York-based hospital system, since 2020.
"Offering science- and research-based health care to transgender and gender diverse youth is part of Children's Minnesota's vision of being every family's essential partner in raising healthier children."
U.S. District Judge Brendan A. Hurson denied the administration's request to stay a preliminary injunction that bars federal officials from conditioning or terminating funding for health care providers based on their provision of gender-affirming care to patients under 19.
"We knew right away that any shift in policy that was being reported was a grave exaggeration," Sheldon said, pointing to GLMA's role within the AMA's House of Delegates, where it has a voting seat and direct visibility into policymaking.
"This bill has traded on a story of health equality and health access. But the real purpose of this bill continues to be targeting trans and gender-diverse patients and their providers throughout the state of Tennessee."
Hospitals cannot legally refuse to treat a patient because of who they are. The decision to stop providing gender-affirming care is unconscionable and discriminatory against transgender patients.
House Bill 754 is put forward as a measure to make insurance companies that cover gender-affirming care also provide coverage for "detransition procedures", it goes much further, mandating the collection of sensitive details from providers including patient treatment timelines, prescription or surgery information, a patient's location data, and a patient's age and biological sex.
Republican-appointed judges reversed a ruling which blocked the ban, arguing with little evidence that gender-affirming care for trans adults was "dangerous," urging states not to fund what it spuriously described as "experimental procedures." It further claimed that trans people had become "disdainful of their sex" and claimed, again without evidence, that banning such provisions would "encourage citizens to appreciate their sex."
NHS England is "separately reviewing the evidence for the use of MAF in adults with gender dysphoria" with the aim of launching a consultation on its findings in late 2026. A separate section clarifies that its ban on new prescriptions will only apply to youth gender services, adding that the NHS will continue to prescribe hormones for adult patients in its gender identity clinics (GICs).